Patent Law Weblog
recent posts
- USPTO Moves to Protect Design Rights for Digital Innovations
- Judicial Conduct and Disability Committee Has Its Say, Denies Judge Newman’s Latest Request for Review
- PTAB Issues Judgment on Priority in CRISPR Interference
- Parties File Supplemental Priority Statements in CRISPR Interference
- Why the Alice Test is Stupid, Part V: The Goalposts Keep Moving
about
Category: Patent Legislation
-
By Donald Zuhn — As part of its ongoing "Conversations With" series, the Washington Legal Foundation (WLF) recently made available its latest question-and-answer offering, which examines the ongoing evolution of intellectual property rights in the United States and internationally. In the paper, entitled "The Changing Legal Landscape For Intellectual Property," former Attorney General and…
-
By Donald Zuhn — Yesterday, as President-elect Barack Obama addressed hundreds of thousands of Chicagoans in Grant Park and millions of viewers around the world, we took a look back at a number of prior Patent Docs reports that discussed some aspects of the President-elect's technology platform, including his positions on patent issues and…
-
By Donald Zuhn — Like many Americans, we spent Tuesday evening watching the presidential election returns come in, and now that Senator Barack Obama has been elected the 44th president of the United States, we thought it would be a good idea to take a look back at some of our previous reports discussing…
-
By Donald Zuhn — On Wednesday Senator Barack Obama and Senator John McCain will be participating in their third, and final, presidential debate. While the third debate will address the economy and domestic policy issues, there is a strong likelihood, particularly in view of the current financial crisis, that U.S. patent policy will draw little…
-
By Donald Zuhn — A study in last month’s issue of Nature Biotechnology calls into question the perception that litigation rates — at least for one particular industry — are rising. The study, entitled "DNA-based patents: an empirical analysis" (the full text of the article can be obtained here for $32), was conducted…
-
By Kevin E. Noonan — Yesterday, we reported on the introduction of a new patent reform bill (S. 3600) in the Senate (see "Senator Kyl’s Patent Reform Bill Introduced Today"). Soon after Senator Jon Kyl’s (R-AZ) patent reform bill was introduced, the Biotechnology Industry Organization (BIO) released a statement in which BIO President…
-
By Kevin E. Noonan — During this Congress, the biotech and pharma sectors appeared to be caught flat-footed in the face of a concerted effort by information technology companies and their affiliated pressure groups (like the Coalition for Patent Fairness) to "reform" patent law out of effective existence. Not this time: Senator Jon…
-
By Donald Zuhn — Last month, we reported on the lobbying expenditures for fourteen biotech and pharma companies and organizations in the second quarter of 2008. Recent news reports have allowed us to add four more companies to the list: • Sanofi-Aventis’ U.S. subsidiary spent more than $1.2 million on second quarter lobbying…
-
By Kevin E. Noonan — Earlier today, Patent Docs participated in a conference call with Jim Greenwood, the President and CEO of the Biotechnology Industry Organization (BIO) and Joshua Boger, Ph.D., Chairman of BIO’s Board and President and CEO of Vertex Pharmaceuticals Inc. Mr. Greenwood, who represented Pennsylvania’s Eighth District in the U.S.…
-
By Donald Zuhn — Regular Patent Docs readers have likely noticed that we have been paying close attention to the lobbying efforts of various players in the biotech/pharma industry. Our interest in the lobbying expenditures of these companies and organizations stems from the push by Congress over the past year to pass patent…
Patent Docs 